Streetbeat News

Stock Prices

ELTX

Elicio Therapeutics, Inc. (NASDAQ:ELTX) announced it will present new preliminary data from its AMPLIFY-7P Phase 1/2 study of ELI-002 7P, a cancer vaccine candidate for mKRAS-driven solid tumors, at the 2024 ASCO Annual Meeting. The study focuses on the vaccine's safety and efficacy in patients with minimal residual disease-positive pancreatic and colorectal cancer. ELI-002 7P targets seven KRAS mutations, aiming to stimulate an immune response in 25% of all solid tumors.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:41 pm

EADSY

Airbus is currently in discussions with China regarding a potential aircraft order, according to a report by Reuters. This development could signify a significant sales boost for Airbus if the negotiations are successful.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:40 pm

CCS

Wedbush analyst Jay McCanless reiterates an Underperform rating on Century Communities (NYSE:CCS) with a maintained price target of $82.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:40 pm

OMQS

OMNIQ Corp's shares surged following the announcement of a follow-on order for its AI-based machine vision solution, aimed at a Homeland Security project. This development signifies the company's continued involvement and success in providing critical technology solutions for national security.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:38 pm

HONE

HarborOne Bancorp (NASDAQ:HONE) reported Q1 earnings of $0.17 per share, surpassing the $0.11 estimate, a 6.25% increase from last year. Sales reached $30.58M, beating the $29.25M estimate but marking an 11.09% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:36 pm

HAFC

Hanmi Financial has announced a new share repurchase authorization allowing the company to buy back up to 1.5 million shares. This move is part of Hanmi's strategy to enhance shareholder value and potentially improve earnings per share by reducing the number of shares outstanding.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:36 pm

DIA

IWM

QQQ

QQQM

SPY

Major stock indexes declined due to weaker-than-anticipated US GDP growth, indicating a slowdown in economic expansion.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:35 pm

BA

SPR

Boeing Co. (NYSE:BA) shares dropped following quarterly results, with analyst Brian Langenberg highlighting the importance of a potential Spirit AeroSystems (NYSE:SPR) buyout and a new CEO for recovery. Langenberg maintains a Buy rating on Boeing with a $275 price target, emphasizing the long-term effort required for Boeing's turnaround. The potential acquisition of Spirit AeroSystems and the selection of a CEO focused on engineering and long-term health are seen as critical steps.

Portfolio Pulse from Shanthi Rexaline

April 25, 2024 | 12:35 pm

MGRX

Mangoceuticals, Inc. (NASDAQ:MGRX), specializing in men's health and wellness products, has acquired a global patent portfolio from Intramont Technologies, Inc. for $20M, paid through the issuance of 980K of 6% Series C Convertible Preferred Shares. This portfolio includes patents for an oral solution aimed at combating a range of infections, including the common cold, respiratory diseases, and HPV.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:34 pm

CALX

Jefferies analyst George Notter downgraded Calix (NYSE:CALX) from Buy to Hold and reduced the price target from $48 to $30, indicating a more cautious outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:34 pm